EMERYVILLE, Calif., Dec. 6, 2010 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host an investor teleconference and webcast. Investigators will discuss data presentations surrounding carfilzomib in multiple myeloma, as featured at the 52nd American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida.
The virtual event will begin at 10:00 a.m. ET on December 7, 2010. The live webcast will be available at:
or by dialing 847-585-4405 and using the passcode 28465587. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3042 and using the passcode 28465587# later in the day. The replay will be available on the Onyx website through December 21, 2010.
About Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.
Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.
SOURCE Onyx Pharmaceuticals, Inc.